03/05/2024 | Press release | Distributed by Public on 03/04/2024 20:03
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") announced that it has received an Excellence Award for the integrated report "Corporate Report 2023" published by Ono at the Nikkei Integrated Report Award 2023 held by Nikkei Inc.
Among 475 companies and organizations who took part in the Nikkei Report Award 2023, 3 companies were selected for the Grand Prize, 6 for the Semi-Grand Prize, and 42 for Excellence (including our company), after evaluation by a panel comprising fund managers and analysts from financial institutions, academic experts, and others.
For more details, visit the following website: https://adnet.nikkei.co.jp/a/nira/index.html
The following points were mainly evaluated for our winning the Excellence Award (extracted from the comments of reviewers):
Ono has been continuously committed to further enhancing information disclosure, including integrated report, so that stakeholders can easily understand the latest situation on our corporate stance, management policies and strategies.
The Nikkei Annual Report Award has been held by Nikkei Inc. every year since 1998 with the aim of further enhancing and promoting annual reports published by Japanese companies. From 2021, the award name was changed from the "Nikkei Annual Report Award" to the "Nikkei Integrated Report Award", and the review system was multi-layered and expanded, and the award system was reorganized and enlarged.